Camrelizumab In Combination With Apatinib As Second-Line Treatment For Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Open-Label, Phase Ii Study

Feng Wang,Junsheng Wang,Tao Wu,Yonggui Hong,Xiangrui Meng,Zhonghai Ren,Yanzhen Guo,Xiuli Yang,Pei Shi,Jiamei Yang,Qingxia Fan

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 4|浏览9

暂无评分

摘要

215Background: Esophageal squamous cell carcinoma (ESCC) is a lethal cancer with a high unmet medical need. Camrelizumab, an anti-PD-1 monoclonal antibody, significantly improved overall survival (...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要